A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer

✍ Scribed by Whang, Young E.; Armstrong, Andrew J.; Rathmell, W. Kimryn; Godley, Paul A.; Kim, William Y.; Pruthi, Raj S.; Wallen, Eric M.; Crane, Jeffrey M.; Moore, Dominic T.; Grigson, Gayle; Morris, Karla; Watkins, Catharine P.; George, Daniel J.

• Book ID: 122020902
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 220 KB
• Volume: 31
• Category: Article
• ISSN: 1078-1439
• DOI: 10.1016/j.urolonc.2010.09.018